# Protectivity and Safety Following Recombinant Hepatitis B Vaccine

> **NCT03919578** · PHASE2,PHASE3 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 536 (actual)

## Conditions studied

- Immunogenicity

## Interventions

- **BIOLOGICAL:** Recombinant Hepatitis B vaccine
- **BIOLOGICAL:** Recombinant Hepatitis B (Bio Farma)

## Key facts

- **NCT ID:** NCT03919578
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-11
- **Primary completion:** 2020-01-30
- **Final completion:** 2020-02-28
- **Target enrollment:** 536 (ACTUAL)
- **Last updated:** 2022-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03919578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03919578, "Protectivity and Safety Following Recombinant Hepatitis B Vaccine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03919578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*